(Q35995534)

11 August 2017

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis (English)

1 reference

11 August 2017

0 references

0 references

10

Norah A Terrault

1 reference

11 August 2017

Varun Saxena

1

1 reference

11 August 2017

Lisa Nyberg

2

1 reference

11 August 2017

Marypat Pauly

3

1 reference

11 August 2017

Aditi Dasgupta

4

1 reference

11 August 2017

Anders Nyberg

5

1 reference

11 August 2017

Barbara Piasecki

6

1 reference

11 August 2017

Bradley Winston

7

1 reference

11 August 2017

Jacquelyn Redd

8

1 reference

11 August 2017

Joanna Ready

9

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 June 2015

1 reference

11 August 2017

1 reference

11 August 2017

62

1 reference

11 August 2017

3

1 reference

11 August 2017

715-725

1 reference

Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander?

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4549204

23 September 2018

Identifiers

DOI

10.1002/HEP.27922

1 reference

11 August 2017

1 reference

11 August 2017

1 reference